Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Palobiofarma SL

Zydus Cadila Joins IO Therapy League With XOMA Tie-up

Cadila Healthcare has entered the immuno-oncology race by inking a licensing agreement with US-based XOMA for a drug candidate that combines the Indian firm's interleukin-2 with the latter’s novel anti-IL-2 monoclonal antibody

Commercial Research & Development

Corvus Aims To Master Adenosine Mechanisms For PD-1/L1 Failures

Emerging Company Profile: CEO Richard Miller, who co-founded Idec and Pharmacyclics, explains Corvus's approach of building a pipeline around an emerging target in cancer immunity that may be complementary to checkpoint inhibitors and other therapies.

StartUps and SMEs ImmunoOncology

Venture Funding Deals: $688.8m In Financings From Avitide To Zai Lab

June venture capital financings for emerging companies totaled more than $688.8m, ranging from an undisclosed round for Avitide to a $120m Series B for Rubius Therapeutics.

Financing Deals

Novartis Oncology Strategy: Focus On The Microenvironment

As ASCO approaches, Novartis tries to highlight its oncology offerings, despite a very early immuno-oncology pipeline.

BioPharmaceutical Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
UsernamePublicRestriction

Register